57.82

1.06% -0.65

Halozyme Therapeutics Inc (HALO)

Overview News Price History Option Chain Financials Why HALO Down? Discussions Forecast

Halozyme Therapeutics Inc stock is traded at $57.82, with a volume of 465.46K. It is down -1.06% in the last 24 hours and down -2.25% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Previous Close:

$58.47

Open:

$58

24h Volume:

465.46K

Relative Volume:

0.35

Market Cap:

$7.29B

Revenue:

$873.30M

Net Income/Loss:

$337.29M

P/E Ratio:

30.76

EPS:

1.88

Net Cash Flow:

$408.32M

1W Performance:

+14.24%

1M Performance:

-2.25%

6M Performance:

+44.95%

1Y Performance:

+62.59%

1-Day Range:

$57.09

$58.17

1-Week Range:

$50.01

$59.39

52-Week Range:

$33.15

$65.53

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name

Halozyme Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(858) 794-8889

Address

12390 EL CAMINO REAL, SAN DIEGO, CA

Employee

373

Twitter

@halozymeinc

Next Earnings Date

2024-10-31

Latest SEC Filings

HALO's Discussions on Twitter

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-24-23	Downgrade	Goldman	Buy → Neutral
Jul-24-23	Initiated	H.C. Wainwright	Buy
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Berenberg	Buy
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform
Dec-21-22	Resumed	Morgan Stanley	Overweight
Nov-28-22	Initiated	Wells Fargo	Overweight
Sep-09-22	Initiated	Morgan Stanley	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral
Jan-21-21	Reiterated	The Benchmark Company	Buy
Dec-17-20	Initiated	Berenberg	Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jul-01-20	Initiated	The Benchmark Company	Buy
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-08-20	Initiated	Goldman	Buy
Nov-05-19	Upgrade	Barclays	Underweight → Equal Weight
Oct-19-18	Resumed	Piper Jaffray	Neutral
May-11-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-24-18	Initiated	Goldman	Neutral
Oct-16-17	Reiterated	Piper Jaffray	Overweight
Jan-06-17	Downgrade	Citigroup	Buy → Neutral
Nov-03-16	Initiated	Deutsche Bank	Buy
Dec-04-15	Initiated	Wells Fargo	Outperform
Nov-18-15	Initiated	Citigroup	Buy
Sep-22-15	Initiated	Barclays	Overweight
Jun-22-15	Reiterated	JP Morgan	Overweight
Mar-03-15	Reiterated	UBS	Buy
Feb-18-15	Reiterated	MLV & Co	Buy
Jan-08-15	Reiterated	MLV & Co	Buy

View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

12:24 PM

Halozyme: Looking For More Growth Following Record Q3 Earnings (NASDAQ:HALO) - Seeking Alpha

12:24 PM

04:09 AM

New York State Teachers Retirement System Purchases 14,489 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

04:09 AM

Nov 04, 2024

H.C. Wainwright lifts Halozyme stock target, buy rating on strong earnings - Investing.com Australia

Nov 04, 2024

Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat

Nov 04, 2024

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance

Nov 04, 2024

Halozyme stock price target, rating held on earnings beat By Investing.com - Investing.com UK

Nov 04, 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Reduced by Assenagon Asset Management S.A. - MarketBeat

Nov 04, 2024

Nov 03, 2024

Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance

Nov 03, 2024

Nov 02, 2024

12,729 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by VELA Investment Management LLC - MarketBeat

Nov 02, 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 02, 2024

(HALO) Technical Data - Stock Traders Daily

Nov 02, 2024

Nov 01, 2024

Halozyme Announces Record Earnings, Guidance - Yahoo Finance

Nov 01, 2024

Earnings call: Halozyme raises full-year guidance on strong Q3 performance - Investing.com

Nov 01, 2024

Halozyme Therapeutics (NASDAQ:HALO) Shares Gap Up After Analyst Upgrade - MarketBeat

Nov 01, 2024

HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up - Nasdaq

Nov 01, 2024

HC Wainwright Issues Positive Forecast for Halozyme Therapeutics (NASDAQ:HALO) Stock Price - MarketBeat

Nov 01, 2024

Stephens Investment Management Group LLC Sells 62,174 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Nov 01, 2024

Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say - MSN

Nov 01, 2024